Outlook Therapeutics reports Q2 FY2026 financial results for quarter ended March 31, 2026

Outlook Therapeutics filed an 8-K to announce its second fiscal quarter 2026 financial results for the period ending March 31, 2026. The company issued a press release on May 15, 2026 containing the actual financial details, which was attached as an exhibit to the filing. This is a routine quarterly earnings disclosure required by SEC regulations.

Retail investors should note that the 8-K itself does not contain the actual financial figures, revenue numbers, earnings per share, or management commentary. Those details are in the press release exhibit. To understand the company's financial performance, cash position, and business progress during the quarter, investors will need to review the full press release. Watch for the company's 10-Q filing in the coming weeks, which will provide complete financial statements, management discussion and analysis, and detailed footnotes that offer deeper insight into the quarter's results and the company's financial condition.